Mandate

Vinge advised LKAB in connection with its investment in the sustainable rare earth elements producer REEtec.

November 08, 2022 Banking and Finance

Vinge has advised Luossavaara-Kiirunavaara AB (publ) (“LKAB”) in connection with its investment in, REEtec Holding AS (“REEtec”). LKAB invests in the financing round, that totals NOK 1.2 billion, to become the largest shareholder of REEtec.

REEtec has developed an innovative and sustainable technology for the separation of rare earth elements and the new financing will be used to finance the construction of its first separation plant which will be located in Herøya, Norway. The REEtec process combines high efficiency with up to 90 per cent. lower carbon emissions.

The demand for rare earth elements, which is driven by e.g. production of electric cars and wind turbines, is expected to increase fivefold by 2030. As Europe is dependent on imports of these critical minerals, LKAB’s investment in REEtec is underpinning the European Union’s strategy to increase Europe’s self-sufficiency. The new separation plant in Herøya will have a production of 720 tonnes of the earth elements Neodymium and Praseodymium, equivalent to five per cent. of Europe's needs and the majority of the production will be sold to the car industry. A second plant is planned to be built in Herøya in 2026, which will also process material from LKAB’s extraction of rare earth elements from mine tailings, processed in the industrial park in Luleå that is planned for production from 2027.

Wiersholm acted as legal counsel to LKAB as to Norwegian law and PwC acted as financial advisor to LKAB.

Vinge’s team consisted of Olof Jisland, Albert Wållgren and Arvid Weimers.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025